Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.

Kramer VG, Varsaneux O, Oliviera M, Colby-Germinario SP, Mesplède T, Wainberg MA.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):7-14. doi: 10.1097/QAI.0000000000000223.

PMID:
24872133
[PubMed - in process]
2.

HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.

Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J.

AIDS. 2007 Mar 30;21(6):693-702.

PMID:
17413690
[PubMed - indexed for MEDLINE]
3.

Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.

Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, Schuitemaker H.

J Virol. 2007 Aug;81(16):8533-42. Epub 2007 May 23.

PMID:
17522228
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.

Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW.

J Virol. 2005 Apr;79(8):4991-9.

PMID:
15795284
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.

Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, Siripanyaphinyo U, Wichukchinda N, Tokunaga K, Yasunaga T, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M.

Microbes Infect. 2009 Mar;11(3):334-43. doi: 10.1016/j.micinf.2008.12.008. Epub 2008 Dec 27.

PMID:
19136072
[PubMed - indexed for MEDLINE]
6.

Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.

Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, van Nuenen AC, Schuitemaker H.

Virology. 2009 Aug 1;390(2):348-55. doi: 10.1016/j.virol.2009.05.028. Epub 2009 Jun 17.

PMID:
19539340
[PubMed - indexed for MEDLINE]
Free Article
7.

Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.

Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, Tressler R, Sloan RD, Wainberg MA.

Antimicrob Agents Chemother. 2012 Aug;56(8):4154-60. doi: 10.1128/AAC.00409-12. Epub 2012 May 21.

PMID:
22615275
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.

Utachee P, Isarangkura-na-ayuthaya P, Tokunaga K, Ikuta K, Takeda N, Kameoka M.

Retrovirology. 2014 Apr 23;11:32. doi: 10.1186/1742-4690-11-32.

PMID:
24758333
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Antigenic properties of the HIV envelope on virions in solution.

Ray K, Mengistu M, Yu L, Lewis GK, Lakowicz JR, DeVico AL.

J Virol. 2014 Feb;88(3):1795-808. doi: 10.1128/JVI.03048-13. Epub 2013 Nov 27. Erratum in: J Virol. 2014 May;88(10):5901. Yu, Lei [added].

PMID:
24284318
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.

Nakowitsch S, Quendler H, Fekete H, Kunert R, Katinger H, Stiegler G.

AIDS. 2005 Nov 18;19(17):1957-66.

PMID:
16260901
[PubMed - indexed for MEDLINE]
11.

Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.

Revilla A, Delgado E, Christian EC, Dalrymple J, Vega Y, Carrera C, González-Galeano M, Ocampo A, de Castro RO, Lezaún MJ, Rodríguez R, Mariño A, Ordóñez P, Cilla G, Cisterna R, Santamaría JM, Prieto S, Rakhmanova A, Vinogradova A, Ríos M, Pérez-Álvarez L, Nájera R, Montefiori DC, Seaman MS, Thomson MM.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):889-901. doi: 10.1089/AID.2010.0177. Epub 2011 Feb 16.

PMID:
21226626
[PubMed - indexed for MEDLINE]
12.

sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates.

Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA.

Retrovirology. 2010 Feb 16;7:11. doi: 10.1186/1742-4690-7-11.

PMID:
20158904
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.

Lai RP, Yan J, Heeney J, McClure MO, Göttlinger H, Luban J, Pizzato M.

PLoS Pathog. 2011 Dec;7(12):e1002442. doi: 10.1371/journal.ppat.1002442. Epub 2011 Dec 15.

PMID:
22194689
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.

Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, Fischer M, Stiegler G, Katinger H, Olson WC, Weber R, Aceto L, Günthard HF, Trkola A.

J Virol. 2005 Jul;79(13):8454-69.

PMID:
15956589
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.

Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, Robinson J, Burton DR, Bell J, Simmonds P, Ball J, Clapham PR.

Retrovirology. 2008 Jan 18;5:5. doi: 10.1186/1742-4690-5-5.

PMID:
18205925
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.

Sagar M, Akiyama H, Etemad B, Ramirez N, Freitas I, Gummuluru S.

J Infect Dis. 2012 Apr 15;205(8):1248-57. doi: 10.1093/infdis/jis183. Epub 2012 Mar 6.

PMID:
22396600
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Divergent effects of cell environment on HIV entry inhibitor activity.

Rusert P, Mann A, Huber M, von Wyl V, Gunthard HF, Trkola A.

AIDS. 2009 Jul 17;23(11):1319-27.

PMID:
19579289
[PubMed - indexed for MEDLINE]
18.

Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).

Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF.

Antimicrob Agents Chemother. 2006 May;50(5):1773-9.

PMID:
16641449
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR.

J Virol. 2005 Jan;79(2):1252-61.

PMID:
15613352
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.

Zhou N, Fan L, Ho HT, Nowicka-Sans B, Sun Y, Zhu Y, Hu Y, McAuliffe B, Rose B, Fang H, Wang T, Kadow J, Krystal M, Alexander L, Colonno R, Lin PF.

Virology. 2010 Jul 5;402(2):256-61. doi: 10.1016/j.virol.2010.03.033. Epub 2010 Apr 18.

PMID:
20400170
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk